{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T05:01:42Z","timestamp":1751086902203},"reference-count":21,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2022]]},"DOI":"10.3960\/jslrt.21018","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T22:09:47Z","timestamp":1640642987000},"page":"18-24","source":"Crossref","is-referenced-by-count":2,"title":["Bendamustine-induced rash is associated with a favorable prognosis in patients with indolent B-cell lymphoma"],"prefix":"10.3960","volume":"62","author":[{"given":"Naoki","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Tanae","sequence":"additional","affiliation":[{"name":"Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Kohri","sequence":"additional","affiliation":[{"name":"Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Asou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsugumi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pathology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Kayano","sequence":"additional","affiliation":[{"name":"Department of Pathology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Asou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Hirschberg E, Gellhorn A, Gump WS. Laboratory evaluation of a new nitrogen mustard, 2-[di-(2-chloroethyl)amino-methyl]benzimidazole, and of other 2-chloroethyl compounds. Cancer Res. 1957; 17: 904-910."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Leoni LM, Bailey B, Reifert J <i>et al.<\/i> Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008; 14: 309-317.","DOI":"10.1158\/1078-0432.CCR-07-1061"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Ohmachi K, Ando K, Ogura M <i>et al.<\/i>. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010; 101: 2059-2064.","DOI":"10.1111\/j.1349-7006.2010.01635.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Rummel MJ, Niederle N, Maschmeyer G <i>et al.<\/i> Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381: 1203-1210.","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Rummel M, Kaiser U, Balser C <i>et al.<\/i> Study Group Indolent Lymphomas. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016; 17: 57-66.","DOI":"10.1016\/S1470-2045(15)00447-7"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Czuczman MS, Goy A, Lamonica D <i>et al.<\/i> Phase II study of bendamustine combined with rituximab in relapsed\/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Ann Hematol. 2015; 94: 2025-2032.","DOI":"10.1007\/s00277-015-2478-9"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Flinn IW, van der Jagt R, Kahl BS <i>et al.<\/i> Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014; 123: 2944-2952.","DOI":"10.1182\/blood-2013-11-531327"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Barbarroja-Escudero J, Sanchez-Gonzalez MJ, Antolin-Amerigo D, Rodriguez-Rodriguez M, Alvarez-Mon M. Hypersensitivity reactions and drug fever by bendamustine: a case report of three patients. Allergol Int. 2015; 64: 109-111.","DOI":"10.1016\/j.alit.2014.08.011"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Carilli A, Favis G, Sundharkrishnan L, Hajdenberg J. Severe dermatologic reactions with bendamustine: a case series. Case Rep Oncol. 2014; 7: 465-470.","DOI":"10.1159\/000365324"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Kusano Y, Terui Y, Yokoyama M, Hatake K. Lichenoid drug eruption associated with Bendamustine. Blood Cancer J. 2016; 6: e438.","DOI":"10.1038\/bcj.2016.48"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008; 13: 725-732.","DOI":"10.1634\/theoncologist.2008-0012"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Shikdar S, Totton D, Turco T, Rachshtut M. Presentation and management of the delayed type of hypersensitivity reaction with bendamustine. Anticancer Drugs. 2018; 29: 814-816.","DOI":"10.1097\/CAD.0000000000000660"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Bell\u00f3n T. Mechanisms of severe cutaneous adverse reactions: recent advances. Drug Saf. 2019; 42: 973-992.","DOI":"10.1007\/s40264-019-00825-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 LaCasce AS, Bociek RG, Sawas A <i>et al.<\/i> Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018; 132: 40-48.","DOI":"10.1182\/blood-2017-11-815183"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Cencini E, Sicuranza A, Fabbri A <i>et al.<\/i> Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab. Br J Haematol. 2019; 184: 223-231.","DOI":"10.1111\/bjh.15582"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Uchida M, Mori Y, Akiba K <i>et al.<\/i> Risk factors for skin toxicities associated with bendamustine-based chemotherapy in patients with non-Hodgkin lymphoma. Biol Pharm Bull. 2020; 43: 1577-1582.","DOI":"10.1248\/bpb.b20-00428"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Nishikori M, Kitano T, Kobayashi M <i>et al.<\/i> Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine. Int J Hematol. 2015; 102: 53-58.","DOI":"10.1007\/s12185-015-1791-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Ishida T, Fujiwara H, Nosaka K <i>et al.<\/i> Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002. J Clin Oncol. 2016; 34: 4086-4093.","DOI":"10.1200\/JCO.2016.67.7732"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004; 4: 314-322.","DOI":"10.1038\/nrc1323"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Reddy N, Hernandez-Ilizaliturri FJ, Deeb G <i>et al.<\/i> Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008; 140: 36-45.","DOI":"10.1111\/j.1365-2141.2007.06841.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Kudo K, Hotta K, Bessho A <i>et al.<\/i> Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol. 2016; 77: 1005-1009.","DOI":"10.1007\/s00280-015-2910-9"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/1\/62_21018\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T22:17:39Z","timestamp":1700000259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/1\/62_21018\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.21018","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"21018"}}